Skip to main content
NIH funding notice PAR-18-514

Testing Lifespan-Healthspan-Extension Interventions in the Models of Alzheimers Disease (AD/ADRD) (R41/R42 Clinical Trial Not Allowed)

Closed on January 5, 2021.

Posted
December 20, 2017
Close date
January 5, 2021
Activity codes
Not stated on the notice page
Institutes taking part
Not stated on the notice page

Read the notice on Grants.gov · NIH Guide page

The notices it replaced

Its page was not saved, so the notices it replaced are not known.

Who won it before

1 competing award (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $349,643 in first-year total cost, median $349,643.

Most frequent study sections

  1. Special Emphasis Panel[ZRG1 ETTN-H (11)]1

Most frequent institutions

  1. OROCHEM TECHNOLOGIES, INC.1
Competing awards under PAR-18-514 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
2020A Novel DHA Treatment Approach for Alzheimer's Disease1R41AG069619-01LAYDEN, BRIAN THOMASOROSKAR, ASHA ANILSUBBAIAH, PAPASANI VOROCHEM TECHNOLOGIES, INC., IL$349,643ZRG1

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.